Leprosy - Revision history

Danbot: Add peer-reviewed reference

2026-03-22T10:16:47Z

Add peer-reviewed reference

← Older revision		Revision as of 10:16, 22 March 2026
Line 1:		Line 1:
	==Background==		==Background==
	*Also known as Hansen's Disease		*Also known as Hansen's Disease<ref>White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015;28(1):80-94. PMID 25567223</ref>
	*Infectious disease caused by Mycobacterium leprae		*Infectious disease caused by Mycobacterium leprae
	*Most new cases found in developing countries		*Most new cases found in developing countries

Danbot: Add Rifampin and Dapsone AntibioticDose entries

2026-03-20T10:59:00Z

Add Rifampin and Dapsone AntibioticDose entries

← Older revision		Revision as of 10:59, 20 March 2026
Line 59:		Line 59:
	***[[Dapsone]] 100mg daily + [[Rifampin]] 600mg daily + [[Clofazimine]] 50mg daily		***[[Dapsone]] 100mg daily + [[Rifampin]] 600mg daily + [[Clofazimine]] 50mg daily
	*Refer patient: National Hansen’s Disease Programs 1-800-642-2477 Http://www.hrsa.gov/hansensdisease/		*Refer patient: National Hansen’s Disease Programs 1-800-642-2477 Http://www.hrsa.gov/hansensdisease/


			===Antibiotic Dosing===
			====Adult====
			*{{AntibioticDose\|drug=Rifampin\|dose=Paucibacillary, single lesion; 600 mg PO x1 with [[ofloxacin]] and [[minocycline]]; Paucibacillary; 600 mg PO qmo x 6mo with [[dapsone]]; Multibacillary; 600 mg PO qmo x 12mo with [[dapsone]] and [[clofazimine]]\|context=Hansen Disease\|disease=Leprosy\|population=Adult}}
			*{{AntibioticDose\|drug=Dapsone\|dose=paucibacillary: 100mg PO QD x6mo; Use with rifampin; multibacillary: 100mg PO QD x12mo; Use with rifampin, clofazimine\|context=Hansen's disease (leprosy)\|disease=Leprosy\|population=Adult}}
			====Pediatric====
			*{{AntibioticDose\|drug=Rifampin\|dose=Paucibacillary, 10-14 yo; 450mg PO qmo x6mo with [[dapsone]]; Paucibacillary, 15+ yo; 600 mg PO qmo x 6mo with [[dapsone]]; Multibacillary, 10-14 yo; 450mg PO qmo x 12mo with [[dapsone]] and [[clofazimine]]; Multibacillary, 15+ yo; 600 mg PO qmo x 12mo with [[dapsone]] and [[clofazimine]]\|context=Hansen Disease\|disease=Leprosy\|population=Pediatric}}

	==Disposition==		==Disposition==

ClaireLewis: /* Management */

2019-09-20T17:43:53Z

Management

← Older revision		Revision as of 17:43, 20 September 2019
Line 58:		Line 58:
	**Treat for twenty-four months with all three:		**Treat for twenty-four months with all three:
	***[[Dapsone]] 100mg daily + [[Rifampin]] 600mg daily + [[Clofazimine]] 50mg daily		***[[Dapsone]] 100mg daily + [[Rifampin]] 600mg daily + [[Clofazimine]] 50mg daily
	*Refer patient:		*Refer patient: National Hansen’s Disease Programs 1-800-642-2477 Http://www.hrsa.gov/hansensdisease/
	National Hansen’s Disease Programs
	~~1770 Physicians Park Drive~~
	~~Baton Rouge, Louisiana 70816~~
	1-800-642-2477
	Http://www.hrsa.gov/hansensdisease/

	==Disposition==		==Disposition==

ClaireLewis at 17:43, 20 September 2019

2019-09-20T17:43:12Z

← Older revision		Revision as of 17:43, 20 September 2019
Line 25:		Line 25:

	==Clinical Features==		==Clinical Features==
	*Hypopigmented or red patches of skin		*Hypopigmented or red [[rash\|patches]] of skin
	**Diminished sensation or lost sensation within patches		**Diminished sensation or lost sensation within patches
	*Paresthesias		*[[Paresthesias]]
	*Painless wounds on hands or feet		*Painless wounds on hands or feet
	*Lumps on earlobes or face		*Lumps on earlobes or face
Line 38:		Line 38:
	*[[Sarcoidosis]]		*[[Sarcoidosis]]
	*[[Syphilis]]		*[[Syphilis]]
	*Erythema nodosum		*[[Erythema nodosum]]
	*[[Erythema multiforme]]		*[[Erythema multiforme]]
	*Cutaneous tuberculosis		*Cutaneous [[tuberculosis]]
	*[[Vitiligo]]		*[[Vitiligo]]
	*[[Scleroderma]]		*[[Scleroderma]]
	*[[Tinea versicolor]]		*[[Tinea versicolor]]
	*Mycosis fungoides		*Mycosis fungoides
	*Diffuse cutaneous leishmaniasis		*Diffuse cutaneous [[leishmaniasis]]
	*Neuropathy of other etiology		*[[Neuropathy]] of other etiology

	==Evaluation==		==Evaluation==
Line 54:		Line 54:
	*Tuberculoid: TT and BT		*Tuberculoid: TT and BT
	**Treat for twelve months with both:		**Treat for twelve months with both:
	***Dapsone 100mg daily + Rifampin 600mg daily		***[[Dapsone]] 100mg daily + [[Rifampin]] 600mg daily
	*Lepromatous: LL, BL, BB		*Lepromatous: LL, BL, BB
	**Treat for twenty-four months with all three:		**Treat for twenty-four months with all three:
	***Dapsone 100mg daily + Rifampin 600mg daily + Clofazimine 50mg daily		***[[Dapsone]] 100mg daily + [[Rifampin]] 600mg daily + [[Clofazimine]] 50mg daily
	*Refer patient:		*Refer patient:
	National Hansen’s Disease Programs		National Hansen’s Disease Programs
Line 66:		Line 66:

	==Disposition==		==Disposition==
	*

	==Complications==		==Complications==

Neil.m.young: Text replacement - "==Diagnostic Evaluation==" to "==Evaluation=="

2016-07-28T03:23:16Z

Text replacement - "==Diagnostic Evaluation==" to "==Evaluation=="

← Older revision		Revision as of 03:23, 28 July 2016
Line 48:		Line 48:
	*Neuropathy of other etiology		*Neuropathy of other etiology

	==~~Diagnostic~~ Evaluation==		==Evaluation==
	*Diagnosis made by skin biopsy		*Diagnosis made by skin biopsy

Ostermayer: Text replacement - "Category:TropMed" to "Category:Tropical Medicine"

2016-03-22T16:59:07Z

Text replacement - "Category:TropMed" to "Category:Tropical Medicine"

← Older revision		Revision as of 16:59, 22 March 2016
Line 81:		Line 81:


	[[Category:~~TropMed~~]]		[[Category:Tropical Medicine]]
	[[Category:ID]]		[[Category:ID]]

Mholtz at 08:49, 6 September 2015

2015-09-06T08:49:29Z

← Older revision		Revision as of 08:49, 6 September 2015
Line 3:		Line 3:
	*Infectious disease caused by Mycobacterium leprae		*Infectious disease caused by Mycobacterium leprae
	*Most new cases found in developing countries		*Most new cases found in developing countries
	*Level 3 Countries with higher numbers of cases include: India, Brazil, Indonesia, Bangladesh, Nigeria		**Level 3 Countries with higher numbers of cases include: India, Brazil, Indonesia, Bangladesh, Nigeria
	*Means of transmission not fully understood; likely respiratory.		*Means of transmission not fully understood - likely respiratory.
	*Has variety of clinical and histopathologic manifestations due to broad range of cellular immune response		*Has variety of clinical and histopathologic manifestations due to broad range of cellular immune response

	==Classification==		===Classification===
	*Disease spectrum ranges from strong immune reaction and few organisms (tuberculoid) to weak immune reaction and numerous organisms (lepromatous)		*Disease spectrum ranges from strong immune reaction and few organisms (tuberculoid) to weak immune reaction and numerous organisms (lepromatous)
	*Categories		*Categories
Line 17:		Line 17:
	**Indeterminate (I)		**Indeterminate (I)

	==Risk Factors==		===Risk Factors===
	*Close contact		*Close contact with infected person
	*Type of leprosy in the contact (lepromatous may be more contagious than tuberculoid)		**Type of leprosy in the contact (lepromatous may be more contagious than tuberculoid)
	*Armadillo exposure		*Armadillo exposure
	*Increased age		*Increased age
	*Genetic influences		*Genetic influences

	==~~Presentation~~==		==Clinical Features==
	*Consider leprosy in patients who have skin lesions that do not respond to conventional treatments or when there are associated sensory disturbances		*Hypopigmented or red patches of skin
			**Diminished sensation or lost sensation within patches
			*Paresthesias
			*Painless wounds on hands or feet
			*Lumps on earlobes or face
			*Tender, enlarged peripheral nerves

			''Consider leprosy in patients who have skin lesions that do not respond to conventional treatments or when there are associated sensory disturbances''

	==Differential Diagnosis==		==Differential Diagnosis==
Line 41:		Line 48:
	*Neuropathy of other etiology		*Neuropathy of other etiology

	==~~Manifestations==~~		==Diagnostic Evaluation==
	*Hypopigmented or red patches of skin
	*Diminished sensation or lost sensation within patches
	*Paresthesias
	*Painless wounds on hands or feet
	*Lumps on earlobes or face
	*Tender, enlarged peripheral nerves

	~~==Work Up~~==
	*Diagnosis made by skin biopsy		*Diagnosis made by skin biopsy

	==Management==		==Management==
	*The National Hansen's Disease Program recommends:		*Tuberculoid: TT and BT
	**Tuberculoid: TT and BT		**Treat for twelve months with both:
	***Treat for twelve months with both:		***Dapsone 100mg daily + Rifampin 600mg daily
	****Dapsone 100mg daily + Rifampin 600mg daily		*Lepromatous: LL, BL, BB
	**Lepromatous: LL, BL, BB		**Treat for twenty-four months with all three:
	***Treat for twenty-four months with all three:		***Dapsone 100mg daily + Rifampin 600mg daily + Clofazimine 50mg daily
	****Dapsone 100mg daily + Rifampin 600mg daily + Clofazimine 50mg daily
	*Refer patient:		*Refer patient:
	National Hansen’s Disease Programs		National Hansen’s Disease Programs
Line 66:		Line 64:
	1-800-642-2477		1-800-642-2477
	Http://www.hrsa.gov/hansensdisease/		Http://www.hrsa.gov/hansensdisease/

			==Disposition==
			*

	==Complications==		==Complications==
	*Immunologic reaction that can occur before or during treatment. Presentation can include: fatigue, malaise, fever, neuritis, arthritis, iritis, nasopharyngeal symptoms		*Immunologic reaction that can occur before or during treatment. Presentation can include: fatigue, malaise, fever, neuritis, arthritis, iritis, nasopharyngeal symptoms

	==~~Sources~~==		==External Links==
	*~~UpToDate~~		*[http://www.hrsa.gov/hansensdisease/ National Hansen's Disease Program]
	*Diagnosaurus
	*National Hansen's Disease Program Http://www.hrsa.gov/hansensdisease/		==See Also==
	*Wright SW, Jack M. Chapter 21. Tropical Medicine. In: Knoop KJ, Stack LB, Storrow AB, Thurman R. eds. The Atlas of Emergency Medicine, 3e. New York, NY: McGraw-Hill; 2010.
	*http:/~~/www.ncbi.nlm.nih.gov/pubmed/10805626~~
			==References==
			<References/>


	[[Category:TropMed]]		[[Category:TropMed]]
	[[Category:ID]]		[[Category:ID]]

Catierey: added links

2015-09-04T17:06:26Z

added links

← Older revision		Revision as of 17:06, 4 September 2015
Line 28:		Line 28:

	==Differential Diagnosis==		==Differential Diagnosis==
	*~~Systemic lupus erythematosus~~		*[[SLE]]
	*Sarcoidosis		*[[Sarcoidosis]]
	*Syphilis		*[[Syphilis]]
	*Erythema nodosum		*Erythema nodosum
	*Erythema multiforme		*[[Erythema multiforme]]
	*Cutaneous tuberculosis		*Cutaneous tuberculosis
	*Vitiligo		*[[Vitiligo]]
	*Scleroderma		*[[Scleroderma]]
	*Tinea versicolor		*[[Tinea versicolor]]
	*Mycosis fungoides		*Mycosis fungoides
	*Diffuse cutaneous leishmaniasis		*Diffuse cutaneous leishmaniasis

Rossdonaldson1 at 22:04, 23 December 2014

2014-12-23T22:04:49Z

← Older revision		Revision as of 22:04, 23 December 2014
Line 76:		Line 76:
	*Wright SW, Jack M. Chapter 21. Tropical Medicine. In: Knoop KJ, Stack LB, Storrow AB, Thurman R. eds. The Atlas of Emergency Medicine, 3e. New York, NY: McGraw-Hill; 2010.		*Wright SW, Jack M. Chapter 21. Tropical Medicine. In: Knoop KJ, Stack LB, Storrow AB, Thurman R. eds. The Atlas of Emergency Medicine, 3e. New York, NY: McGraw-Hill; 2010.
	*http://www.ncbi.nlm.nih.gov/pubmed/10805626		*http://www.ncbi.nlm.nih.gov/pubmed/10805626

			[[Category:TropMed]]
			[[Category:ID]]

JBeckEsmay: edit

2014-12-21T15:47:23Z

edit

← Older revision		Revision as of 15:47, 21 December 2014
Line 7:		Line 7:
	*Has variety of clinical and histopathologic manifestations due to broad range of cellular immune response		*Has variety of clinical and histopathologic manifestations due to broad range of cellular immune response

	==~~classification~~==		==Classification==
	*Disease spectrum ranges from strong immune reaction and few organisms (tuberculoid) to weak immune reaction and numerous organisms (lepromatous)		*Disease spectrum ranges from strong immune reaction and few organisms (tuberculoid) to weak immune reaction and numerous organisms (lepromatous)
	*Categories		*Categories